deltatrials
Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06859424

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (ACCELERATE)

Sponsor: Center for International Blood and Marrow Transplant Research

Conditions AML (Acute Myelogenous Leukemia) Acute Leukemia (Category) Acute Lymphoid Leukemia (ALL) CLL (Chronic Lymphocytic Leukemia) CML (Chronic Myelogenous Leukemia) Chronic Myelomonocytic Leukemia (CMML) Lymphoma MDS (Myelodysplastic Syndrome) Myelofibrosis Myeloproliferative Neoplasm (MPN) Prolymphocyctic Leukemia
Interventions Conditioning Regimen A Conditioning Regimen B Conditioning Regimen C Conditioning Regimen D Conditioning Regimen E Hematopoietic Cell Transplantation PTCy (25 mg/kg D3, D4) PTCy (50 mg/kg D3, D4) Permitted Concomitant Therapy Post-transplant Abatacept Post-transplant Mycophenolate mofetil Post-transplant Ruxolitinib Post-transplant Tacrolimus Prohibited Concomitant Therapy Study treatment compliance Supportive Care: Blood Products Supportive Care: Growth Factors Supportive Care: Infection Prophylaxis Supportive Care: Intravenous immune globulin (IVIG) Supportive Care: Lipid elevations Supportive Care: Monitoring and management of CRS Supportive Care: Prophylaxis against infections Supportive Care: Seizure prophylaxis
Updated 3 times since 2025 Last updated: Sep 3, 2025 Started: Jul 25, 2025 Primary completion: Jun 30, 2028 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06859424, this PHASE2 trial focuses on AML (Acute Myelogenous Leukemia) and Acute Leukemia (Category) and remains actively recruiting participants. Sponsored by Center for International Blood and Marrow Transplant Research, it has been updated 3 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2025 – ~Aug 2025 · 4 months · monthly snapshotNot Yet Recruiting~Aug 2025 – ~Oct 2025 · 2 months · monthly snapshotRecruiting~Oct 2025 – present · 10 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE2

  2. Aug 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Apr 2025 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Center for International Blood and Marrow Transplant Research
  • Incyte Corporation
  • National Marrow Donor Program
Data source: Center for International Blood and Marrow Transplant Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations